Natalizumab: Increased vigilance is required in treating patients with multiple sclerosis

Michael K. Racke; Olaf Stüve

doi:10.1177/1756285608099125

Natalizumab: Increased vigilance is required in treating patients with multiple sclerosis

Michael K. Racke, Olaf Stüve

Research output: Contribution to journal › Editorial › peer-review

Original language	English (US)
Pages (from-to)	155-156
Number of pages	2
Journal	Therapeutic Advances in Neurological Disorders
Volume	1
Issue number	3
DOIs	https://doi.org/10.1177/1756285608099125
State	Published - Nov 2008

ASJC Scopus subject areas

Pharmacology
Neurology
Clinical Neurology

Access to Document

10.1177/1756285608099125

Cite this

@article{fa7babde32c84599a5f601fc47d188b6,

title = "Natalizumab: Increased vigilance is required in treating patients with multiple sclerosis",

author = "Racke, {Michael K.} and Olaf St{\"u}ve",

year = "2008",

month = nov,

doi = "10.1177/1756285608099125",

language = "English (US)",

volume = "1",

pages = "155--156",

journal = "Therapeutic Advances in Neurological Disorders",

issn = "1756-2856",

publisher = "SAGE Publications Ltd",

number = "3",

}

TY - JOUR

T1 - Natalizumab

T2 - Increased vigilance is required in treating patients with multiple sclerosis

AU - Racke, Michael K.

AU - Stüve, Olaf

PY - 2008/11

Y1 - 2008/11

UR - http://www.scopus.com/inward/record.url?scp=84993820012&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84993820012&partnerID=8YFLogxK

U2 - 10.1177/1756285608099125

DO - 10.1177/1756285608099125

M3 - Editorial

C2 - 21180573

AN - SCOPUS:84993820012

SN - 1756-2856

VL - 1

SP - 155

EP - 156

JO - Therapeutic Advances in Neurological Disorders

JF - Therapeutic Advances in Neurological Disorders

IS - 3

ER -

Natalizumab: Increased vigilance is required in treating patients with multiple sclerosis

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this